Bli medlem
Bli medlem

Du är här


Novartis International AG: Novartis shareholders approve all resolutions proposed by Board of Directors

Novartis International AG / Novartis shareholders approve all resolutions
proposed by Board of Directors. Processed and transmitted by NASDAQ OMX
Corporate Solutions. The issuer is solely responsible for the content of this
* Shareholders approve 19thconsecutive dividend increase to CHF 2.70 (+4%)
per share for 2015
* Dr. Joerg Reinhardt confirmed by shareholders as Chairman of the Novartis
Board of Directors as well as all other members who have stood for
re-election; Ton Buechner and Elizabeth Doherty elected as new members of
the Board
* Shareholders authorize the Board of Directors to execute share buybacks
within the framework of a seventh share repurchase program that will allow
Novartis to repurchase shares for cancellation up to a maximum of CHF 10
* Shareholders approve all other proposals of the Board of Directors,
including the 2015 compensation report as well as future Board and
Executive Committee compensation

Basel, February 23, 2016
- More than 97% of Novartis shareholders today followed the Board of
Directors' recommendations for all proposed resolutions at the Group's Annual
General Meeting. A total of 1,776 shareholders were present at the meeting
held in Basel, representing approximately 61.6% of the issued shares of

Shareholders approved the nineteenth consecutive dividend increase per share
since the creation of Novartis in 1996, with an increase of 4% to CHF 2.70
for 2015 compared to CHF 2.60 for 2014. Payment for the 2015 dividend will be
made with effect from February 29, 2016.

Votes on Compensation for the Members of the Board of Directors and the
Executive Committee

Shareholders approved in two separate binding votes the total maximum amount
of compensation for the members of the Board of Directors covering the period
from the 2016 AGM to the 2017 AGM and the total maximum amount of
compensation in respect of 2017 for the members of the Executive Committee.
Furthermore, shareholders endorsed in an advisory vote the 2015 Compensation

Annual re-election and election of Members of the Board

A large majority of shareholders re-elected Dr. Joerg Reinhardt as Chairman
of the Board of Directors and each member of the Board of Directors who stood
for re-election for one year. Further, shareholders elected Ton Buechner and
Elizabeth Doherty as new members of the Board of Directors. Dr. Verena Briner
decided not to stand for re-election. The Board of Directors thanks her for
her services and commitment to Novartis as a Director and member of the Board
of Director's Risk Committee.

In addition, shareholders re-elected the following members of the Board of
Directors to the Compensation Committee for one year: Srikant Datar, Ph.D.,
Ann Fudge, Enrico Vanni, Ph.D. and William T. Winters. The Committee will be
chaired by Enrico Vanni and each member will serve until the end of the next
Annual General Meeting.

Furthermore, in line with the Board of Director's recommendation, shareholders
also approved the cancelation of 49,878,180 shares repurchased on the second
trading line under the sixth share repurchase program in the financial year
2015 and to reduce the share capital accordingly by CHF 24,939,090, from CHF
1,338,496,500 to CHF 1,313,557,410.

For a detailed listing of all resolutions presented at the 2016 Annual General
Meeting, please


The foregoing release contains forward-looking statements that can be
identified by terminology such as "authorize," "will," "recommendations,"
"advisory," "recommendation," or similar expressions, or by express or
implied discussions regarding the potential future impact on Novartis of the
matters described in this release, including matters involving the seventh
share repurchase program and involving compensation of the Board of Directors
and the Executive Committee. You should not place undue reliance on these
statements. Such forward-looking statements reflect the current views of
management regarding future events, and involve known and unknown risks,
uncertainties and other factors that may cause actual results to be
materially different from any future results, performance or achievements
expressed or implied by such statements. There can be no guarantee as to the
ultimate outcome of the matters described in this release. In particular,
management's expectations regarding these matters could be affected by, among
other things, unexpected impacts of these matters on Novartis, including on
its management and on its financial results; the potential impact of these
matters on the competitiveness of Novartis or competition in general; the
public reaction to these matters; the impact that the foregoing factors could
have on the values attributed to the Novartis Group's assets and liabilities
as recorded in the Group's consolidated balance sheet, and other risks and
factors referred to in Novartis AG's current Form 20-F on file with the US
Securities and Exchange Commission. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those anticipated, believed,
estimated or expected. Novartis is providing the information in this press
release as of this date and does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of new
information, future events or otherwise.

About Novartis

Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland,
Novartis offers a diversified portfolio to best meet these needs: innovative
medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the
only global company with leading positions in these areas. In 2015, the Group
achieved net sales of USD 49.4 billion, while R&D throughout the Group
amounted to approximately USD 8.9 billion (USD 8.7 billion excluding
impairment and amortization charges). Novartis Group companies employ
approximately 119,000 full-time-equivalent associates. Novartis products are
available in more than 180 countries around the world. For more information,
please visit

Novartis is on Twitter. Sign up to follow @Novartis

Novartis Media Relations

| Central media line : |
|+41 61 324 2200 |
| Eric Althoff Dermot Doherty |
| |
|Novartis Global Media Relations Novartis Global Media Relations |
|+41 61 324 7999 (direct) +41 61 696 8653 (direct) |
|+41 79 593 4202 (mobile) +41 79 536 9755 (mobile) |
| |

Novartis Investor Relations

| Central phone: +41 61 324 7944 North America: |
| Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448 |
| Pierre-Michel Bringer +41 61 324 1065 Sloan Pavsner +1 212 830 2417 |
| Thomas Hungerbuehler +41 61 324 8425 |
| Isabella Zinck +41 61 324 7188 |
| |
| |

Media release (PDF)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.